Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?

被引：28

作者：

Enjoji, Munechika ^{[1
]}

Nakamuta, Makoto ^{[2
,3
]}

机构：

[1] Fukuoka Univ, Fac Pharmaceut Sci, Dept Clin Pharmacol, Jonan Ku, Fukuoka 81401809, Japan

[2] Natl Hosp Org, Kyushu Med Ctr, Dept Gastroenterol, Chuo Ku, Fukuoka 8108563, Japan

[3] Natl Hosp Org, Kyushu Med Ctr, Clin Res Ctr, Chuo Ku, Fukuoka 8108563, Japan

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2010年 / 16卷 / 07期

关键词：

Cholesterol; Ezetimibe; Nonalcoholic fatty liver disease; NPC1L1; Polyunsaturated fatty acids; ACID-METABOLISM; NONOBESE PATIENTS; GENE-EXPRESSION; STEATOHEPATITIS; STEATOSIS; INSULIN; SREBP-1C; OBESE; MODEL;

D O I：

10.3748/wjg.v16.i7.800

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

In our examination of the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD), non-obese NAFLD patients without insulin resistance presented a characteristic pattern of dietary intake. Dietary cholesterol intake was superabundant in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Namely, excess cholesterol intake appears to be one of the main factors associated with NAFLD development and liver injury. Therefore, the control of dietary cholesterol intake may lead to an improvement in NAFLD, and the NPC1L1 inhibitor ezetimibe might be a promising treatment for NAFLD. We review one pathogenic aspect of lipid metabolism dysregulation in NAFLD and survey new strategies for NAFLD treatment based on the modification of cholesterol metabolism. (C) 2010 Baishideng. All rights reserved.

引用

页码：800 / 803

页数：4

共 28 条

[1] Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): A cross-sectional study [J].

Allard, Johane P. ;

Aghdassi, Elaheh ;

Mohammed, Saira ;

Raman, Maitreyi ;

Avand, Ghazal ;

Arendt, Bianca M. ;

Jalali, Pegah ;

Kandasamy, Thileep ;

Prayitno, Nita ;

Sherman, Morris ;

Guindi, Maha ;

Ma, David W. L. ;

Heathcote, Jenny E. .

JOURNAL OF HEPATOLOGY, 2008, 48 (02) :300-307

[2]

Allison S J, 2009, NAT REV GASTRO HEPAT, V6, P320

[3]

Bhardwaj Sidharth S, 2007, Clin Liver Dis, V11, P597, DOI 10.1016/j.cld.2007.06.010

[4] Molecular mediators of hepatic steatosis and liver injury [J].

Browning, JD ;

Horton, JD .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (02) :147-152

[5] Recent advances in nonalcoholic fatty liver disease [J].

Cheung, Onpan ;

Sanyal, Arun J. .

CURRENT OPINION IN GASTROENTEROLOGY, 2009, 25 (03) :230-237

[6] Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia [J].

Davies, JP ;

Scott, C ;

Oishi, K ;

Liapis, A ;

Ioannou, YA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (13) :12710-12720

[7] Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome [J].

Deushi, Michiyo ;

Nomura, Mitsunori ;

Kawakami, Akio ;

Haraguchi, Mihoko ;

Ito, Mizuho ;

Okazaki, Mitsuyo ;

Ishii, Hideto ;

Yoshida, Masayuki .

FEBS LETTERS, 2007, 581 (29) :5664-5670

[8]

ENJOJI M, 2009, HEPATOL INT

[9]

Enjoji M, 2009, AM J CASE REP, V10, P148

[10] Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease [J].

Higuchi, Nobito ;

Kato, Masaki ;

Shundo, Yuki ;

Tajiri, Hirotaka ;

Tanaka, Masatake ;

Yamashita, Naoki ;

Kohjima, Motoyuki ;

Kotoh, Kazuhiro ;

Nakamuta, Makoto ;

Takayanagi, Ryoichi ;

Enjoji, Munechika .

HEPATOLOGY RESEARCH, 2008, 38 (11) :1122-1129

← 1 2 3 →